- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cervical cancer
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Pembrolizumab – March 2025
Pembrolizumab; Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
12 March 2025